1 Study Matches
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
This is a study of the drug DFMO (difluoromethylornithine) for neuroblastoma that has returned or not responded to treatment. DFMO is an oral drug that inhibits a certain enzyme (protein) in blood which is associated with a bad outcome in neuroblastoma cases. Cancer cells have pathways that drive the cancer to grow and DFMO targets the specific pathway of this enzyme to turn these cells off.
Suzanne Treadway - at firstname.lastname@example.org or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
Inclusion Criteria:Up to 31 years old with history of relapsed/refractory neuroblastoma.
Completed upfront therapy with at least 4 cycles of aggressive multi-drug chemotherapy
Exclusion Criteria:Received a dose of DFMO in combination with etoposide
Currently receiving another investigational drug